|Tested species reactivity||Human|
|Published species reactivity||Human, Not Applicable|
|Host / Isotype||Rabbit|
|Immunogen||A synthetic peptide derived from near the N-terminus of human beta-catenin|
|Storage buffer||tissue culture supernatant|
|Contains||15mM sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:125|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA5-14461 targets beta-Catenin in IHC (P) applications and shows reactivity with Human samples.
The MA5-14461 immunogen is a synthetic peptide derived from near the N-terminus of human beta-catenin.
The catenins (alpha, beta and gamma) are ubiquitously expressed, cytoplasmic proteins associated with E-cadherin at cellular junctions. beta-catenin also binds to N-cadherin and co-immunoprecipitates with APC. Cadherin/catenin complexes are linked to the cytoskeleton via a direct association between alpha-actinin and alpha-catenin. Increased tyrosine phosphorylation can disrupt catenin-cadherin complexes, influencing cellular adhesion. Mutations in the catenin gene, CTNNB1, have been implicated in its accumulation and various forms of carcinomas.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Serous carcinoma arising from uterine adenomyosis/adenomyotic cyst of the cervical stump: a report of 3 cases.
MA5-14461 was used in immunohistochemistry to study 3 cases of uterine adenomyosis/adenomyotic cysts of the cervical stump leading to serous carcinoma
|Lu B,Chen Q,Zhang X,Cheng L||Diagnostic pathology (11:null)||2016|
A mouse model of human primitive neuroectodermal tumors resulting from microenvironmentally-driven malignant transformation of orthotopically transplanted radial glial cells.
MA5-14461 was used in immunohistochemistry - paraffin section to describe a mouse model to study primitive neuroectodermal tumors
|Malchenko S,Sredni ST,Hashimoto H,Kasai A,Nagayasu K,Xie J,Margaryan NV,Seiriki K,Lulla RR,Seftor RE,Pachman LM,Meltzer HY,Hendrix MJ,Soares MB||PloS one (10:null)||2015|